Floatz logo

Cilengitide

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 3BBB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BBB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 2BB

View all 50 →

Same molecule, other indications

Cilengitide is also rated in:

adult glioblastomaDormant
B
Indicative ·
61 / 100
View asset →
gliosarcomaDormant
B
Indicative ·
61 / 100
View asset →
giant cell glioblastomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →